Newron Presents 2024 Financial Results and Provides 2025 Outlook [Yahoo! Finance]
ADC Therapeutics SA Common Shares (ADCT)
Company Research
Source: Yahoo! Finance
biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial results and operational highlights for the business year ended December 31, 2024, and provided an outlook for 2025. Highlights 2024: Evenamide Exceptional data from study 014/015 and study 008A: Demonstrated significant and increasing efficacy of evenamide as an add-on therapy on multiple measures of psychopathology in treatment-resistant schizophrenia (TRS) and chronic schizophrenia Confirmed evenamide's favorable safety and tolerability profile The data adds to the growing evidence that evenamide's glutamatergic inhibition mechanism of action offers an innovative therapeutic option to schizophrenia patients who are not benefiting from current antipsychotic treatments on the market Strategic licensing and partnerships: In December 2024, the Company announced a licensing agreement with EA Pharma,
Show less
Read more
Impact Snapshot
Event Time:
ADCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADCT alerts
High impacting ADC Therapeutics SA Common Shares news events
Weekly update
A roundup of the hottest topics
ADCT
News
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCTPR Newswire
- ADC Therapeutics updates data from Phase 1b trial of Zynlonta in lymphoma [Yahoo! Finance]Yahoo! Finance
- ADC Therapeutics (NYSE:ADCT) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.MarketBeat
- ADC Therapeutics SA (ADCT) Discusses Updated Results From LOTIS-7 Trial Evaluating ZYNLONTA Plus Glofitamab in Relapsed or Refractory DLBCL Transcript [Seeking Alpha]Seeking Alpha
- ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma [Yahoo! FinanceYahoo! Finance
ADCT
Earnings
- 11/10/25 - Beat
ADCT
Sec Filings
- 12/15/25 - Form EFFECT
- 12/12/25 - Form 424B3
- 12/9/25 - Form 4
- ADCT's page on the SEC website